Chest physiotherapy for pneumonia in adults (Protocol)

Yan YP, Wu TX, Yin XL, Wang BY, Liu GJ, Dong BR

This is a reprint of a Cochrane protocol, prepared and maintained by The Cochrane Collaboration and published in The Cochrane Library 2008, Issue 1

http://www.thecochranelibrary.com
# Table of Contents

- Abstract ............................................. 1
- Background ........................................ 1
- Objectives ......................................... 2
- Criteria for Considering Studies for This Review ................. 2
- Search Methods for Identification of Studies ......................... 2
- Methods of the Review .................................. 2
- Potential Conflict of Interest ............................. 3
- Acknowledgements ...................................... 3
- Sources of Support ...................................... 4
- References ........................................... 4
- Cover Sheet .......................................... 5
Chest physiotherapy for pneumonia in adults (Protocol)

Yan YP, Wu TX, Yin XL, Wang BY, Liu GJ, Dong BR

This record should be cited as:

This version first published online: 24 January 2007 in Issue 1, 2007.
Date of most recent substantive amendment: 08 November 2006

ABSTRACT

This is the protocol for a review and there is no abstract. The objectives are as follows:
To assess the benefits and harms of chest physiotherapy for pneumonia in adults.

BACKGROUND

Pneumonia is most commonly caused by bacteria but is occasionally caused by viruses, fungi, parasites and other infectious agents. It is the leading cause of mortality from an infectious disease (Niederman 2001). Pneumonia is typically classified as either community-acquired pneumonia (CAP) or hospital-acquired pneumonia (nosocomial pneumonia (NP)). The most serious form of NP, ventilator-associated pneumonia, arises in patients who are being mechanically ventilated for other reasons. It is estimated that the annual cost of treating CAP in the United States is $12.2 billion (Colice 2004) and has an average mortality rate of 14% (Fine 1990). Nosocomial pneumonia is the second most common nosocomial infection and the leading cause of death from hospital acquired infection (Bowton 1999).

Antibiotics represent the mainstay of pneumonia treatment, while other therapies are primarily supportive. These adjunctive therapies include supplemental oxygen, intravenous hydration and chest physiotherapy (George 1995). Chest physiotherapy is an airway clearance technique that combines manual percussion of the chest wall by a caregiver, strategic positioning of the patient for mucus drainage, and teaching cough and breathing techniques. It assists in treating some of the symptoms of respiratory disorders, such as airflow obstruction, alterations in ventilatory pump functions and impaired exercise performance. The aim is to improve a patient’s respiratory status and expedite recovery by enhancing airway clearance in lung diseases associated with hypersecretion and reduced airway resistance. Increased airway clearance enhances gas exchange and reduces the work of breathing (Wallis 1999).

Chest physiotherapy is best used for patients with copious secretions (more than 30 ml/day) who have a reduced ability to cough (Cochrane 1977; Graham 1978). However, chest physiotherapy may be ineffective and even harmful. It may cause an increase in oxygen consumption (Horiuchi 1997; Weissman 1991; Weissman 1993), bronchospasm (Campbell 1975), induce hypertension, increase oxygen demand (Horiuchi 1997; Weissman 1993), lead to hypoxaemia (Connors 1980; Poelaert 1991) and even cause rib fractures (Chalumeau 2002).

Chest physiotherapy for cystic fibrosis, acute bronchiolitis and patients being mechanically ventilated have been reviewed (Flenady 2002; Perrotta 2005; Schans 2000). Schans was not able to source any robust evidence to support a beneficial or harmful effect of chest physiotherapy in people with cystic fibrosis (Schans 2000). Perrotta suggested that percussion and vibration techniques could not be recommended for hospitalised infants with acute bronchiolitis (Perrotta 2005). Flenady concluded that there was inadequate data to assess the benefits and harms associated with active chest physiotherapy for babies being extubated from mechanical ventilation in neonatal intensive care settings (Flenady 2002).

The clinical effectiveness of chest physiotherapy for pneumonia is controversial. Some clinical studies concluded that chest physiotherapy did not hasten the resolution of pneumonia (Graham 1978) or was not useful (Britton 1983; Britton 1985). Two studies suggested that larger or multicentre trials were needed to confirm the findings (Ntoumenopoulos 2002; Tydeman 1989); while others concluded that chest physiotherapy had beneficial effects in patients with pulmonary infection (Hanying 2005). No systematic review or meta-analysis of chest physiotherapy for pneumonia has been published, to our knowledge. This review aims to...
系统性地审查所有随机对照试验（RCTs）和
控制临床试验（CCTs）以评估胸腔物理疗法
对肺炎的疗效。

**Objectives**

To assess the benefits and harms of chest physiotherapy for pneu-
monia in adults.

**Criteria for considering studies for this review**

**Types of studies**

We will consider all RCTs assessing the efficacy of chest phys-
iotherapy for adult patients with any type of pneumonia. Trials
which also include other basic respiratory diseases will be included
if pneumonia is diagnosed; such trials will be analysed separately.
We will exclude the trials in which physiotherapy is administe-
red for prevention of pneumonia, as pneumonia can occur in many
conditions, such as trauma, cerebral vessels disease, postoperative
conditions, and so on. Quasi-randomised controlled trials will also
be considered. Both published and unpublished trials will be in-
cluded.

**Types of participants**

Adult patients (older than 18 years of age) of either gender, with
any type of pneumonia. Pneumonia will be defined by each orig-
inal trial. The diagnostic criteria used by the trial authors will be
described in the ‘Characteristics of Included Studies’ section of the
review.

**Types of intervention**

Chest physiotherapy of any type compared to no chest physio-
therapy. We will include trials using traditional chest physiother-
aphy. Trials using mechanical devices which have the same effect as
traditional chest physiotherapy will also be included. These meth-
ods will be considered: postural drainage, chest percussion, vibra-
tion, thoracic oscillation, chest shaking, huffing, directed cough-
ing, thoracic expansion, forced exhalation or expiration techniques
and manual hyperinflation.

**Types of outcome measures**

**Primary outcomes**

1. Death;
2. Cure rate (proportion of the number of clinically cured patients
of the total number of patients).

**Secondary outcomes**

1. Duration of hospital stay (days);
2. Healing time (days);
3. Rate of clearing of X-ray film;
4. Fever clearance time.

**Adverse events**

We will define serious adverse events, according to the ICH Guide-
lines (CFR & ICH 1997), as any event that: leads to death, is life-
threatening, requires in-patient hospitalisation or prolongation of
existing hospitalisation, results in persistent or significant disabili-
ty; or any important medical event which may have jeopardised
the patient or requires intervention to prevent it. All other adverse
events will be considered non-serious.

**Search methods for identification of studies**

See: Cochrane Acute Respiratory Infections Group methods used
in reviews.

We will search the following databases the Cochrane Central
Register of Controlled Trials (CENTRAL) (The Cochrane Library
latest issue); MEDLINE (1966 to present); EMBASE (1974 to
present); CBMdisc (1978 to present); the National Research
Register (www.update-software.com/National/nrr-frame.html);
and Physiotherapy Evidence Database (PEDro).

The following search terms will be used in MEDLINE in
conjunction with the highly sensitive search strategy suggested in
the Cochrane Handbook for Systematic Reviews of Interventions
4.2.5 (Higgins 2005) for identification of RCTs. These terms
will be modified as appropriate for other databases. We will also
handsearch related journals and references of included studies.
There will be no language restrictions.

(exp Pneumonia/ OR pneumonia$ OR lung inflammation$ OR
exp Respiratory Tract Infections/ OR respiratory tract infection$
OR respiratory infection$)
AND
(exp Physical Therapy Modalities/ OR physical therap$ OR
physiotherapy$ OR physical treatment$ OR exp drainage,
postural/ OR postural drainag$ OR chest clap$ OR chest
percussion OR chest shak$ OR oscillat$ OR exp vibration/ OR
vibration OR directed cough$ OR forced exhalation OR forced
expiration OR exp Positive-Pressure Respiration/ OR positive
pressure ventilation OR positive expiratory pressure OR exp
breathing exercises/ OR breathing exercise$ OR diaphragmatic
breathing OR thoracic expansion exercise$ OR breathing train$
OR ventilatory muscle train$ OR exp Electric Stimulation
Therapy/ OR electrostimulation OR huff$ OR exp massage/
OR massag$ OR exp musculoskeletal manipulations/ OR
hyperinflation).

**Methods of the review**

The contact author will search the literature and two review
authors will independently assess the extracted titles and abstracts
to identify potentially relevant articles. We will exclude the trials

---

系统性地审查所有随机对照试验（RCTs）和
控制临床试验（CCTs）以评估胸腔物理疗法
对肺炎的疗效。

**Objectives**

To assess the benefits and harms of chest physiotherapy for pneu-
monia in adults.

**Criteria for considering studies for this review**

**Types of studies**

We will consider all RCTs assessing the efficacy of chest phys-
iotherapy for adult patients with any type of pneumonia. Trials
which also include other basic respiratory diseases will be included
if pneumonia is diagnosed; such trials will be analysed separately.
We will exclude the trials in which physiotherapy is administe-
red for prevention of pneumonia, as pneumonia can occur in many
conditions, such as trauma, cerebral vessels disease, postoperative
conditions, and so on. Quasi-randomised controlled trials will also
be considered. Both published and unpublished trials will be in-
cluded.

**Types of participants**

Adult patients (older than 18 years of age) of either gender, with
any type of pneumonia. Pneumonia will be defined by each orig-
inal trial. The diagnostic criteria used by the trial authors will be
described in the ‘Characteristics of Included Studies’ section of the
review.

**Types of intervention**

Chest physiotherapy of any type compared to no chest physio-
therapy. We will include trials using traditional chest physiother-
aphy. Trials using mechanical devices which have the same effect as
traditional chest physiotherapy will also be included. These meth-
ods will be considered: postural drainage, chest percussion, vibra-
tion, thoracic oscillation, chest shaking, huffing, directed cough-
ing, thoracic expansion, forced exhalation or expiration techniques
and manual hyperinflation.

**Types of outcome measures**

**Primary outcomes**

1. Death;
2. Cure rate (proportion of the number of clinically cured patients
of the total number of patients).

**Secondary outcomes**

1. Duration of hospital stay (days);
2. Healing time (days);
3. Rate of clearing of X-ray film;
4. Fever clearance time.

**Adverse events**

We will define serious adverse events, according to the ICH Guide-
lines (CFR & ICH 1997), as any event that: leads to death, is life-
threatening, requires in-patient hospitalisation or prolongation of
existing hospitalisation, results in persistent or significant disabili-
ty; or any important medical event which may have jeopardised
the patient or requires intervention to prevent it. All other adverse
events will be considered non-serious.

**Search methods for identification of studies**

See: Cochrane Acute Respiratory Infections Group methods used
in reviews.

We will search the following databases the Cochrane Central
Register of Controlled Trials (CENTRAL) (The Cochrane Library
latest issue); MEDLINE (1966 to present); EMBASE (1974 to
present); CBMdisc (1978 to present); the National Research
Register (www.update-software.com/National/nrr-frame.html);
and Physiotherapy Evidence Database (PEDro).

The following search terms will be used in MEDLINE in
conjunction with the highly sensitive search strategy suggested in
the Cochrane Handbook for Systematic Reviews of Interventions
4.2.5 (Higgins 2005) for identification of RCTs. These terms
will be modified as appropriate for other databases. We will also
handsearch related journals and references of included studies.
There will be no language restrictions.

(exp Pneumonia/ OR pneumonia$ OR lung inflammation$ OR
exp Respiratory Tract Infections/ OR respiratory tract infection$
OR respiratory infection$)
AND
(exp Physical Therapy Modalities/ OR physical therap$ OR
physiotherapy$ OR physical treatment$ OR exp drainage,
postural/ OR postural drainag$ OR chest clap$ OR chest
percussion OR chest shak$ OR oscillat$ OR exp vibration/ OR
vibration OR directed cough$ OR forced exhalation OR forced
expiration OR exp Positive-Pressure Respiration/ OR positive
pressure ventilation OR positive expiratory pressure OR exp
breathing exercises/ OR breathing exercise$ OR diaphragmatic
breathing OR thoracic expansion exercise$ OR breathing train$
OR ventilatory muscle train$ OR exp Electric Stimulation
Therapy/ OR electrostimulation OR huff$ OR exp massage/
OR massag$ OR exp musculoskeletal manipulations/ OR
hyperinflation).

**Methods of the review**

The contact author will search the literature and two review
authors will independently assess the extracted titles and abstracts
to identify potentially relevant articles. We will exclude the trials
which fail to meet the inclusion criteria. Differences will be resolved by a third review author.

Quality assessment of trials
The quality of the trials will be assessed independently by two review authors, based on the generation of the allocation sequence, allocation concealment, blinding and follow up. Finally, we will assess the risk of bias, where A: low risk of bias (all of the criteria met); B: moderate risk of bias (one or more criteria partly met); C: high risk of bias (one or more criteria not met). Differences will be resolved by another review author.

The detailed quality components are as follows:

- Generation of the allocation sequence:
  Adequate (computer generated random numbers, table of random numbers, or similar);
  Unclear (the trial was described as randomised, but the generation of the allocation sequence was not described);
  Inadequate (quasi-randomised trials; non-randomised trials).

- Allocation concealment:
  Adequate (concealed up to the point of treatment by central randomisations, sealed envelopes, or similar);
  Unclear (the allocation concealment procedure was not described);
  Inadequate (open table of random numbers or similar).

- Blinding:
  Adequate (since the intervention of chest physiotherapy can't be completely masked, it will be impossible to have double-blinding. We will consider single-blinding adequate);
  Unclear (if the method of blinding was not described);
  Not performed (if the trial was not blind).

- Follow up:
  Adequate (if the numbers and reasons for dropouts and withdrawals in all intervention groups are described or specified that there were no dropouts or withdrawals);
  Unclear (if the report gave the impression that there had been no dropouts or withdrawals, but was not specifically stated);
  Inadequate (if the number or reasons for dropouts and withdrawals are not described).

Data extraction
Data will be independently extracted by two review authors using a standardised form. We will attempt to contact all trial authors (by e-mail, letter or fax) for additional papers, to confirm data extraction, and to obtain missing data. After completion of the data extraction, the data will be checked by another review author. Pertinent data to be extracted will include, where possible: description of participants (including age, gender, type of pneumonia, severity of pneumonia, basic conditions, setting); description of intervention (details of chest physiotherapy, including type, frequency, intensity, time); description of control therapy; trial design (including design, recruitment, method of randomisation, sample size, trial inclusion and exclusion criteria, withdrawals); description of outcomes (including mortality, duration of hospital stay, adverse events, cure, healing time, rate of clearing of X-ray film, duration of fever); and source of funding.

Data analysis
Any dichotomous data, such as the cure rate or mortality, will be expressed as a relative risk together with a 95% confidence interval (CI). Data for continuous measures will be expressed either as a mean difference (MD) (95% CI) or a standardised mean difference (SMD) (95% CI). The MD will be used if all trials provide data on the same scale, if not the SMD will be used. If a number of trials are available with sufficient uniformity in settings and outcome definitions, we will attempt to pool results by meta-analysis, but if the trials are relatively dissimilar, either statistically or clinically, they will be presented separately. Trials will be combined using Review Manager (Version 4.2.8). A fixed-effect model will be used unless significant heterogeneity is noted, then a random-effects model will be chosen. Heterogeneity in trial results will be assessed by inspecting the forest plots to detect overlapping CIs, applying the chi-squared test with a p-value of 0.10 indicating statistical significance, and implementing the I-squared test (with a value of 50% used to denote moderate levels of heterogeneity). In case of heterogeneity between the studies, efforts will be made to explore sources of heterogeneity due to various factors such as type of pneumonia, type of physiotherapy, and so on. We will graphically check for publication bias by using a funnel plot. Subgroup analyses will be performed, where possible, for the following: age category, different type of chest physiotherapy, different type of pneumonia, and disease severity.

Sensitivity analyses
We will perform sensitivity analyses in order to explore the influence of the following factors on effect size:
1. Repeating the analysis excluding unpublished studies (if there were any);
2. Repeating the analysis taking account of study quality; for example, RCTs with poor methodology;
3. Repeating the analysis excluding studies using any of the following filters: diagnostic criteria, language of publication, source of funding (industry versus other) or country.

POTENTIAL CONFLICT OF INTEREST
None known.

ACKNOWLEDGEMENTS
Thank you to Elizabeth Dooley, Review Group Co-ordinator for
the Cochrane Acute Respiratory Infections Group, for help with writing this protocol; and Ruth Foxlee, Trials Search Co-ordinator for the Cochrane Acute Respiratory Infections Group, for her useful comments on the search strategy. Thank you to the Statistical Editor (Nelcy Rodriguez), Contact Editor (Abigail Fraser), Peer Referees (Jan Poelaert and George Ntoumenopoulos) and Consumer Referees (Mona Nasser and Anne Lyddiatt) of this protocol for their useful comments.

SOURCES OF SUPPORT

External sources of support
• No sources of support supplied

Internal sources of support
• Chinese Cochrane Center, Chinese Centre of Evidence-Based Medicine, West China Hospital of Sichuan University CHINA

REFERENCES

Additional references

Bowton 1999

Britton 1983

Britton 1985

Campbell 1975

CFR & ICH 1997

Chalumeau 2002

Colice 2004

Connors 1980

Fine 1990

Flenady 2002

George 1995

Graham 1978

Hanying 2005

Higgins 2005
Higgins JPT, Green S, editors. Highly sensitive search strategies for identifying reports of randomized controlled trials in
Horiuchi 1997


Niederman 2001


Ntoumenopoulos 2002


Perrotta 2005


Poelaert 1991


Schnans 2000


Teydeman 1989


Wallis 1999


Weissman 1991


Weissman 1993
